Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development

被引:16
作者
Ezzikouri, Sayeh [1 ,2 ]
Nourlil, Jalal [3 ,4 ]
Benjelloun, Soumaya [1 ]
Kohara, Michinori [5 ]
Tsukiyama-Kohara, Kyoko [2 ]
机构
[1] Inst Pasteur Maroc, Virol Unit, Viral Hepatitis Lab, Casablanca, Morocco
[2] Kagoshima Univ, Joint Fac Vet Med, Transboundary Anim Dis Ctr, Kagoshima, Japan
[3] Inst Pasteur Maroc, Med Virol, Casablanca, Morocco
[4] Inst Pasteur Maroc, BSL3 Lab, Casablanca, Morocco
[5] Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Tokyo, Japan
基金
日本学术振兴会;
关键词
Human coronavirus; public health; respiratory viruses; origin; pathogenesis; sars-CoV-2; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; COVID-19; SARS-COV-2; ANTIBODIES; PNEUMONIA; ACE2; NL63; VIRUSES; SPIKE;
D O I
10.1080/21645515.2020.1787068
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19.
引用
收藏
页码:2992 / 3000
页数:9
相关论文
共 102 条
  • [21] The Challenges of Vaccine Development against a New Virus during a Pandemic
    Diamond, Michael S.
    Pierson, Theodore C.
    [J]. CELL HOST & MICROBE, 2020, 27 (05) : 699 - 703
  • [22] Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens
    Diez, Jose-Maria
    Romero, Carolina
    Gajardo, Rodrigo
    [J]. IMMUNOTHERAPY, 2020, 12 (08) : 571 - 576
  • [23] Eastin T., 2020, NEW ENG J MED, V58, P711
  • [24] Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus
    Feng, Youjun
    Gao, George F.
    [J]. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2007, 30 (5-6) : 309 - 327
  • [25] The challenge of emergency medicine facing the COVID-19 outbreak
    Freund, Yonathan
    [J]. EUROPEAN JOURNAL OF EMERGENCY MEDICINE, 2020, 27 (03) : 155 - 155
  • [26] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [27] Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Van Thuan Hoang
    Meddeb, Line
    Sevestre, Jacques
    Mailhe, Morgane
    Doudier, Barbara
    Aubry, Camille
    Amrane, Sophie
    Seng, Piseth
    Hocquart, Marie
    Eldin, Carole
    Finance, Julie
    Vieira, Vera Esteves
    Tissot-Dupont, Herve Tissot
    Honore, Stephane
    Stein, Andreas
    Million, Matthieu
    Colson, Philippe
    La Scola, Bernard
    Veit, Veronique
    Jacquier, Alexis
    Deharo, Jean-Claude
    Drancourt, Michel
    Fournier, Pierre Edouard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    [J]. TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 34
  • [28] The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
    Gorbalenya, Alexander E.
    Baker, Susan C.
    Baric, Ralph S.
    de Groot, Raoul J.
    Drosten, Christian
    Gulyaeva, Anastasia A.
    Haagmans, Bart L.
    Lauber, Chris
    Leontovich, Andrey M.
    Neuman, Benjamin W.
    Penzar, Dmitry
    Perlman, Stanley
    Poon, Leo L. M.
    Samborskiy, Dmitry V.
    Sidorov, Igor A.
    Sola, Isabel
    Ziebuhr, John
    [J]. NATURE MICROBIOLOGY, 2020, 5 (04) : 536 - 544
  • [29] Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
    Hamming, I
    Timens, W
    Bulthuis, MLC
    Lely, AT
    Navis, GJ
    van Goor, H
    [J]. JOURNAL OF PATHOLOGY, 2004, 203 (02) : 631 - 637
  • [30] Identification of a new human coronavirus
    van der Hoek, L
    Pyrc, K
    Jebbink, MF
    Vermeulen-Oost, W
    Berkhout, RJM
    Wolthers, KC
    Wertheim-van Dillen, PME
    Kaandorp, J
    Spaargaren, J
    Berkhout, B
    [J]. NATURE MEDICINE, 2004, 10 (04) : 368 - 373